|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
gptkb:CEO
|
|
gptkbp:approves
|
gptkb:1985
|
|
gptkbp:brand
|
gptkb:Vasotec
Epaned
|
|
gptkbp:clinical_trial
|
Chronic kidney disease
Phase III
Diabetic nephropathy
Post-myocardial infarction
|
|
gptkbp:composed_of
|
Chemical synthesis
|
|
gptkbp:contraindication
|
Pregnancy
Angioedema history
|
|
gptkbp:discovered_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:dosage_form
|
5 to 40 mg daily
|
|
gptkbp:excretion
|
Kidneys
|
|
gptkbp:formulation
|
gptkb:tablet
gptkb:item
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Enalapril
|
|
gptkbp:ingredients
|
C20 H28 N2 O5
|
|
gptkbp:interacts_with
|
gptkb:Lithium
Diuretics
NSAI Ds
|
|
gptkbp:invention
|
gptkb:2002
|
|
gptkbp:is_atype_of
|
C09 A A02
|
|
gptkbp:is_available_on
|
Generic drug
|
|
gptkbp:is_used_for
|
Heart failure
Hypertension
|
|
gptkbp:lifespan
|
11 hours
|
|
gptkbp:manager
|
Oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:India
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
Liver
Enalaprilat
|
|
gptkbp:pharmacokinetics
|
Vasodilation
Prodrug
|
|
gptkbp:provides_information_on
|
gptkb:European_Society_of_Cardiology
gptkb:American_College_of_Cardiology
|
|
gptkbp:research_areas
|
gptkb:hospital
Nephrology
Hypertension management
Heart failure treatment
|
|
gptkbp:side_effect
|
gptkb:Cough
gptkb:Nausea
Dizziness
Fatigue
Hyperkalemia
Rash
Hypotension
Elevated liver enzymes
|
|
gptkbp:traded_on
|
Enalapril Maleate
|
|
gptkbp:type_of
|
75847-73-3
|
|
gptkbp:bfsParent
|
gptkb:ACE_inhibitors
|
|
gptkbp:bfsLayer
|
5
|